Osteoporosis, Internal medicine, Bone mineral, Endocrinology and Bone density are her primary areas of study. Susan L. Greenspan has researched Osteoporosis in several fields, including Placebo, Physical therapy, Surgery and Urology. Her work on Bone Density Conservation Agents, Prospective cohort study, Testosterone deficiency and Thyroid disease as part of general Internal medicine study is frequently connected to Photon absorptiometry, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them.
Her Bone mineral study integrates concerns from other disciplines, such as Hip fracture, Bone disease, Parathyroid hormone, Bone remodeling and Risk factor. When carried out as part of a general Endocrinology research project, her work on Bone resorption, Osteopenia, Bone mass and Testosterone is frequently linked to work in Osteocalcin, therefore connecting diverse disciplines of study. Her Bone density research integrates issues from Hormone, Femur, Thyroid and Hip bone.
Susan L. Greenspan focuses on Osteoporosis, Internal medicine, Bone mineral, Endocrinology and Bone density. Her Osteoporosis research incorporates themes from Longitudinal study, Physical therapy, Surgery and Placebo. In her research on the topic of Physical therapy, Confidence interval is strongly related with Odds ratio.
Her Bone mineral study integrates concerns from other disciplines, such as Radiology, Bisphosphonate and Bone disease. In general Endocrinology study, her work on Hormone, Urine and Resorption often relates to the realm of Osteocalcin and Context, thereby connecting several areas of interest. Her Bone density research includes themes of Orthopedic surgery, Femur and Androgen deprivation therapy.
Susan L. Greenspan mostly deals with Osteoporosis, Internal medicine, Physical therapy, Bone density and Bone mineral. Her work in the fields of Osteoporosis, such as Osteonecrosis of the jaw, intersects with other areas such as Risk assessment. In her study, Abaloparatide is strongly linked to Placebo, which falls under the umbrella field of Internal medicine.
The study incorporates disciplines such as Intervention, Sarcopenia, Randomized controlled trial and Comorbidity in addition to Physical therapy. Her Bone density research incorporates elements of Cross-sectional study, Gynecology and Retrospective cohort study. Her Bone mineral study combines topics from a wide range of disciplines, such as Orthopedic surgery, Surgery, Femoral neck and Urology.
Susan L. Greenspan spends much of her time researching Osteoporosis, Internal medicine, Physical therapy, Bone density and Bone mineral. The concepts of her Osteoporosis study are interwoven with issues in Meta-analysis and Zoledronic acid. Her Endocrinology research extends to Internal medicine, which is thematically connected.
Her Physical therapy research is multidisciplinary, relying on both Prospective cohort study, Randomized controlled trial and Gerontology. Susan L. Greenspan has included themes like Bone health, Observational study, Disease management and Glucocorticoid in her Bone density study. The various areas that she examines in her Bone mineral study include Sarcopenia, Surgery, Radiography, Pelvis and Hazard ratio.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The Effects of Parathyroid Hormone and Alendronate Alone or in Combination in Postmenopausal Osteoporosis
Dennis M. Black;Susan L. Greenspan;Kristine E. Ensrud;Lisa Palermo.
The New England Journal of Medicine (2003)
Fall severity and bone mineral density as risk factors for hip fracture in ambulatory elderly.
Susan L. Greenspan;Elizabeth R. Myers;Lauri A. Maitland;Neil M. Resnick.
Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis
T. Schnitzer;H. G. Bone;G. Crepaldi;S. Adami.
Aging Clinical and Experimental Research (2000)
One Year of Alendronate after One Year of Parathyroid Hormone (1–84) for Osteoporosis
D. M. Black;J. P. Bilezikian;K. E. Ensrud;S. L. Greenspan.
The New England Journal of Medicine (2005)
Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents.
Marc C. Hochberg;Susan Greenspan;Richard D. Wasnich;Paul Miller.
The Journal of Clinical Endocrinology and Metabolism (2002)
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research.
Robert A. Adler;Ghada El-Hajj Fuleihan;Douglas C. Bauer;Pauline M. Camacho.
Journal of Bone and Mineral Research (2016)
Gastric bypass surgery for morbid obesity leads to an increase in bone turnover and a decrease in bone mass.
Penelope S. Coates;John D. Fernstrom;Madelyn H. Fernstrom;Philip R. Schauer.
The Journal of Clinical Endocrinology and Metabolism (2004)
Effect of Recombinant Human Parathyroid Hormone (1-84) on Vertebral Fracture and Bone Mineral Density in Postmenopausal Women with Osteoporosis: A Randomized Trial
Greenspan Sl;Bone Hg;Ettinger Mp;Hanley Da.
Annals of Internal Medicine (2007)
Obesity is not protective against fracture in postmenopausal women: GLOW.
Juliet E. Compston;Nelson B. Watts;Roland D. Chapurlat;Cyrus Cooper.
The American Journal of Medicine (2011)
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Postmenopausal Osteoporosis
Nelson Watts;John Bilezikian;Pauline Camacho;Susan Greenspan.
Endocrine Practice (2010)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: